AmerisourceBergen has entered into an agreement to purchase World Courier Group, Inc. for $520 million in cash. The transaction involves the acquisition of the private company, which specializes in supporting pharmaceutical firms with the testing and handling of complex treatments.
This acquisition is intended to strengthen AmerisourceBergen’s ability to launch and commercialize specialty products. World Courier Group provides transportation, storage, and distribution services for clinical trials to biopharmaceutical companies. Industry observers note that this move may assist AmerisourceBergen in transitioning medications from clinical trials to the commercial market.
Wayne B. Heyland, president of World Courier Group, stated that the integration of the two organizations would be smooth due to shared values and similar corporate cultures. He indicated that the combined entity would be well-positioned to capitalize on growth opportunities, particularly in international markets. Heyland expressed enthusiasm about joining the largest provider of specialty distribution and services globally.
This deal follows other recent acquisitions by AmerisourceBergen. The company previously purchased the TheraCom LLC unit from CVS Caremark Corp. It also completed a smaller acquisition of IntrinsiQ, a firm that assists community oncologists with patient care decisions.
Details regarding the specific timeline for the completion of the transaction or any regulatory approvals required were not provided in the source material.
